Pulse BiosciencesPLSE -3.61%31 Cyclically Adjusted PB Ratio is 15.48 as of Jul. 07, 2026, which is 47% above its 10-year median of 10.54. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 525 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 96.57% on this metric.
The historical rank and industry rank for Pulse Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
PLSE'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.23 Med: 10.54 Max: 16.14
Current: 16.04
During the past years, Pulse Biosciences's highest Cyclically Adjusted PB Ratio was 16.14. The lowest was 7.23. And the median was 10.54.
PLSE's Cyclically Adjusted PB Ratio is ranked worse than 96.57% of 525
companies
in the Medical Devices & Instruments industry
Industry Median: 1.8
vs PLSE: 16.04
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Pulse Biosciences's adjusted book value per share data for the three months ended in Mar. 2026 was $0.972. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.81 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Pulse Biosciences (NAS:PLSE) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Pulse Biosciences Cyclically Adjusted PB Ratio Related Terms
Pulse Biosciences Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences Cyclically Adjusted PB Ratio Chart
PLSE vs LMAT, XRAY, KMTS: Cyclically Adjusted PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Cyclically Adjusted PB Ratio falls into.
Pulse Biosciences Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Pulse Biosciences's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 15.48 mean?
Pulse Biosciences (PLSE) has a Cyclically Adjusted PB Ratio of 15.48 as of Jul. 07, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Pulse Biosciences and its competitors. This is 47% above median its historical median of 10.54. Over the past decade, Pulse Biosciences' Cyclically Adjusted PB Ratio has ranged from 7.23 to 16.14. According to the industry distribution chart, Pulse Biosciences ranks #507 out of 525 companies in the Medical Devices & Instruments industry, placing it in the top 96.6%.
Is Pulse Biosciences' Cyclically Adjusted PB Ratio too high?
Pulse Biosciences' current Cyclically Adjusted PB Ratio of 15.48 is 47% above median its 10-year median of 10.54. Over the past 10 years, this metric has ranged from a low of 7.23 to a high of 16.14. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.80. Pulse Biosciences' value of 15.48 is 760% above this industry median. Based on the distribution chart, Pulse Biosciences ranks #507 out of 525 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Cyclically Adjusted PB Ratio compare to LMAT and XRAY?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #507 out of 525 companies for Cyclically Adjusted PB Ratio. This places Pulse Biosciences in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.80. Pulse Biosciences' value of 15.48 is 760% above this benchmark. Historically, Pulse Biosciences' own Cyclically Adjusted PB Ratio has ranged from 7.23 to 16.14 over the past decade. While the company's 10-year median is 10.54 vs. the industry median of 1.80, Pulse Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.80, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current Cyclically Adjusted PB Ratio of 15.48 is 760% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current Cyclically Adjusted PB Ratio is 15.48, which is 47% above median its own 10-year median of 10.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Cyclically Adjusted PB Ratio of 15.48. The current Cyclically Adjusted PB Ratio is 15.48, which is 47% above median its 10-year median of 10.54 and 760% above the Medical Devices & Instruments industry median of 1.80. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Cyclically Adjusted PB Ratio is 15.48 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
